Czech researchers have discovered that nanoplastics can weaken the lungs’ natural defence system, raising fresh concerns ...
Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) ...
ORJ-001 achieved therapeutic exposure and was well tolerated in Phase 1 study, supporting company’s plans to initiate Phase 2 clinical trial in IPF patients ...
Galaxy Digital Inc. (the "Company" or "Galaxy"), a global leader in digital assets and data center infrastructure, today announced that the New York State Department of Financial Services (NYDFS) has ...
Detailed price information for Galaxy Entmnt Group Ord (GXYEF) from The Globe and Mail including charting and trades.
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the FDA has extended the review period for the ...
Autoimmune pulmonary alveolar proteinosis (aPAP) is a rare, life-threatening lung disease driven by granulocyte–macrophage colony-stimulating factor (GM-CSF) deficiency, which impairs alveolar ...
A major UK-led clinical trial has found that a treatment commonly used to help premature babies breathe offers no benefit for infants on life support with severe bronchiolitis—a seasonal viral illness ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results